Hospital
The Moses H. Cone Memorial Hospital Operating Corporation
The Moses H. Cone Memorial Hospital Operating Corporation was paid $133.12M by Medicaid between Jan 2018 and Dec 2024, across 274 billing codes. Its largest line is 99285, emergency room visit (most serious) — 24% of everything it billed.
33Billing provider infoTHE MOSES H. CONE MEMORIAL HOSPITAL OPERATING CORPORATION
GREENSBORO, NC 27401
GREENSBORO, NC 27401
33aNPI1477591055assigned 06/03/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$133.12M
24GClaims2,217,442
24DCodes billed274
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#3 of 92
Median peer was paid$11.47M
This provider vs. median12×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WARD, ELIZABETH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 319,033 | $13.17M | |
| 2019 | 270,398 | $12.76M | |
| 2020 | 206,385 | $8.32M | |
| 2021 | 288,656 | $16.11M | |
| 2022 | 329,719 | $24.55M | |
| 2023 | 381,805 | $26.78M | |
| 2024incomplete | 421,446 | $31.42M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 24% | 94,992 | 86,686 | $31.71M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 170,138 | 157,628 | $30.93M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 116,830 | 107,785 | $29.06M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.6% | 26,663 | 24,573 | $4.75M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.5% | 17,212 | 14,955 | $1.99M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 14,221 | 13,340 | $1.77M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.3% | 54,233 | 49,058 | $1.77M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.3% | 54,212 | 49,044 | $1.67M |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 37,412 | 34,751 | $1.47M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.0% | 62,095 | 53,706 | $1.35M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 69,984 | 56,289 | $1.32M |
| 80053 | Comprehensive metabolic panel | <1% | 124,132 | 104,472 | $1.14M |
262 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 25,727 | $1.14M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 32,673 | $1.01M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 12,434 | $1.00M |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 35,611 | $956K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 7,496 | $840K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 6,753 | $787K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 112,178 | $777K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 20,124 | $731K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 18,223 | $723K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,424 | $713K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 19,599 | $684K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 932 | $622K |
| T2016 | A day of residential support for a person with a developmental disability | <1% | 2,864 | $622K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 21,773 | $591K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,169 | $590K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 20,490 | $528K |
| 87481 | <1% | 16,897 | $521K | |
| 87511 | <1% | 15,880 | $488K | |
| J3490 | Unclassified drugs | <1% | 129,347 | $460K |
| 85027 | <1% | 65,516 | $429K | |
| 71045 | Radiologic examination, chest; single view | <1% | 9,544 | $425K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 4,758 | $390K |
| 76820 | <1% | 3,896 | $343K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 42,672 | $333K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,095 | $306K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,925 | $292K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14,710 | $290K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 6,666 | $287K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,071 | $274K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 10,154 | $274K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,335 | $258K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 258 | $246K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,731 | $234K |
| 76801 | <1% | 1,957 | $211K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 5,442 | $207K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,919 | $196K |
| S9484 | Crisis intervention mental health services, per hour | <1% | 1,020 | $192K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 17,569 | $186K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 6,110 | $183K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 19,666 | $182K |
| 84702 | <1% | 18,796 | $178K | |
| 84484 | <1% | 23,295 | $175K | |
| 83690 | <1% | 24,885 | $171K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,961 | $156K |
| A9270 | Non-covered item or service | <1% | 291,168 | $151K |
| G0378 | Hospital observation service, per hour | <1% | 1,131 | $148K |
| 81025 | <1% | 16,129 | $132K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,465 | $130K |
| 59025 | Fetal non-stress test | <1% | 1,950 | $123K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,017 | $121K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 2,723 | $116K |
| 87486 | <1% | 2,813 | $115K | |
| 87581 | <1% | 2,813 | $113K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,162 | $109K |
| 81001 | <1% | 31,975 | $108K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,726 | $102K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,686 | $102K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 6,998 | $99K |
| 76818 | <1% | 1,239 | $95K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 266 | $71K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,165 | $70K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,375 | $69K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 10,640 | $63K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,187 | $63K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,360 | $62K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,973 | $62K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,597 | $58K |
| 87631 | <1% | 1,652 | $57K | |
| 87081 | <1% | 6,595 | $55K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 636 | $54K |
| 87210 | <1% | 11,588 | $53K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 944 | $51K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 604 | $46K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 223 | $44K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 902 | $44K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 162 | $44K |
| 77336 | <1% | 446 | $43K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 478 | $38K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,676 | $35K |
| 87660 | <1% | 1,460 | $34K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 122 | $33K |
| 77334 | <1% | 54 | $33K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,861 | $33K |
| 82947 | <1% | 5,986 | $31K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,261 | $30K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,450 | $30K |
| 74018 | <1% | 498 | $29K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 68 | $28K |
| 90686 | <1% | 8,164 | $27K | |
| 82728 | <1% | 2,452 | $26K | |
| 36591 | <1% | 1,588 | $26K | |
| 97597 | <1% | 832 | $25K | |
| 90715 | <1% | 2,943 | $25K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,535 | $23K |
| 83880 | <1% | 655 | $22K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 161 | $21K |
| 90651 | <1% | 1,313 | $21K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 57 | $21K |
| 92567 | <1% | 788 | $21K | |
| 41874 | <1% | 27 | $20K | |
| J0741 | Injection, cabotegravir and rilpivirine, 2mg/3mg | <1% | 141 | $19K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 497 | $19K |
| 96367 | <1% | 668 | $18K | |
| 92579 | <1% | 190 | $18K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,034 | $17K |
| 81003 | <1% | 6,355 | $17K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,338 | $15K |
| 90677 | <1% | 523 | $14K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,459 | $14K |
| 81513 | <1% | 1,090 | $14K | |
| 90474 | <1% | 1,955 | $13K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 96 | $13K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,880 | $13K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 272 | $12K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 245 | $12K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 71 | $12K |
| 0124A | <1% | 193 | $12K | |
| 76830 | Ultrasound, transvaginal | <1% | 83 | $11K |
| 90670 | <1% | 3,300 | $11K | |
| 92587 | <1% | 183 | $11K | |
| 95816 | <1% | 101 | $11K | |
| 83550 | <1% | 1,654 | $10K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 30 | $10K |
| 92588 | <1% | 123 | $10K | |
| 83735 | <1% | 1,952 | $10K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 42 | $9K |
| 84703 | <1% | 784 | $8K | |
| 91320 | <1% | 199 | $8K | |
| 83540 | <1% | 1,654 | $8K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 361 | $7K |
| 76882 | <1% | 140 | $7K | |
| 11981 | <1% | 110 | $7K | |
| 93971 | <1% | 46 | $7K | |
| 90480 | <1% | 209 | $7K | |
| 87428 | <1% | 76 | $6K | |
| 0002A | <1% | 133 | $6K | |
| 83615 | <1% | 1,860 | $6K | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 401 | $6K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 80 | $6K |
| 0054A | <1% | 129 | $6K | |
| 0001A | <1% | 123 | $5K | |
| 93922 | <1% | 262 | $5K | |
| 81002 | <1% | 1,482 | $5K | |
| 90734 | <1% | 931 | $5K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 156 | $5K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,547 | $5K |
| 92557 | <1% | 46 | $5K | |
| 87480 | <1% | 188 | $4K | |
| 82607 | <1% | 441 | $4K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 67 | $4K |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 22 | $4K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 7,101 | $4K |
| 85045 | <1% | 1,519 | $4K | |
| 86900 | <1% | 1,086 | $4K | |
| 86901 | <1% | 1,086 | $4K | |
| 85018 | <1% | 1,188 | $4K | |
| 29581 | <1% | 177 | $4K | |
| 94761 | <1% | 537 | $4K | |
| 77300 | <1% | 13 | $3K | |
| 58300 | <1% | 78 | $3K | |
| J7297 | Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg | <1% | 17 | $3K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,092 | $3K |
| 92552 | <1% | 141 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 156 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 266 | $3K |
| 96127 | <1% | 1,044 | $2K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 401 | $2K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 123 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 136 | $2K |
| 99173 | <1% | 371 | $2K | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 2,933 | $2K |
| 90656 | <1% | 606 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12 | $2K |
| 43450 | <1% | 12 | $2K | |
| 92558 | <1% | 29 | $2K | |
| 0004A | <1% | 39 | $2K | |
| C9399 | Unclassified drugs or biologicals | <1% | 21 | $2K |
| 92551 | <1% | 266 | $2K | |
| 90716 | <1% | 1,901 | $2K | |
| 36416 | <1% | 939 | $2K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 40 | $1K |
| 87077 | <1% | 100 | $1K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 23 | $1K |
| 0051A | <1% | 25 | $1K | |
| 82746 | <1% | 134 | $1K | |
| 99172 | <1% | 86 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 385 | $1K |
| 90707 | <1% | 1,818 | $1K | |
| 0003A | <1% | 27 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 417 | $1K |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 449 | $1K |
| 82962 | <1% | 230 | $961.23 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 530 | $909.88 |
| 0071A | <1% | 13 | $739.40 | |
| 90837 | Psychotherapy session, about an hour | <1% | 18 | $737.19 |
| 88312 | <1% | 12 | $696.06 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 42 | $686.34 |
| 94726 | <1% | 13 | $649.06 | |
| 99205 | Prolong outpt/office vis | <1% | 14 | $641.16 |
| 99201 | <1% | 91 | $639.29 | |
| 86850 | <1% | 37 | $618.12 | |
| J0248 | Injection, remdesivir, 1 mg | <1% | 338 | $612.62 |
| 74019 | <1% | 13 | $609.00 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 95 | $594.09 |
| 82378 | <1% | 57 | $588.06 | |
| 93926 | <1% | 13 | $584.21 | |
| 72110 | <1% | 13 | $581.05 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 101 | $577.55 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 210 | $524.27 |
| 83921 | <1% | 43 | $498.69 | |
| 86592 | <1% | 66 | $426.95 | |
| 20610 | <1% | 15 | $409.16 | |
| V2632 | Posterior chamber intraocular lens | <1% | 14 | $403.07 |
| 96376 | <1% | 82 | $397.34 | |
| 85046 | <1% | 67 | $385.68 | |
| 87186 | <1% | 28 | $382.53 | |
| 90732 | <1% | 14 | $333.30 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 407 | $318.16 |
| 83883 | <1% | 57 | $306.72 | |
| 84165 | <1% | 91 | $293.33 | |
| 90723 | <1% | 2,757 | $283.30 | |
| 85610 | <1% | 75 | $260.37 | |
| 80047 | <1% | 16 | $226.83 | |
| 85379 | <1% | 14 | $221.08 | |
| 90680 | <1% | 2,017 | $211.61 | |
| 83605 | <1% | 14 | $190.75 | |
| 83010 | <1% | 18 | $188.29 | |
| 90647 | <1% | 2,759 | $178.99 | |
| 82570 | <1% | 27 | $158.96 | |
| 82948 | <1% | 46 | $141.73 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 26 | $133.44 |
| 99000 | <1% | 170 | $131.18 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 153 | $115.35 |
| 84156 | <1% | 27 | $112.67 | |
| 87510 | <1% | 187 | $99.96 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 19 | $78.52 |
| 99406 | <1% | 25 | $72.63 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 42 | $70.47 |
| 76813 | <1% | 19 | $68.17 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 13 | $63.12 |
| 90633 | <1% | 2,070 | $59.34 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 15 | $42.81 |
| 90694 | <1% | 12 | $38.76 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 13 | $34.17 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 13 | $28.10 |
| 96523 | <1% | 22 | $27.84 | |
| G0008 | Administration of influenza virus vaccine | <1% | 280 | $25.28 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 15 | $20.90 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 45 | $20.61 |
| 90700 | <1% | 519 | $14.54 | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 89 | $10.85 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 12 | $9.94 |
| J7999 | Compounded drug, not otherwise classified | <1% | 489 | $0.03 |
| 91305 | 0% | 373 | $0.00 | |
| 90696 | 0% | 537 | $0.00 | |
| 91307 | 0% | 35 | $0.00 | |
| 96161 | 0% | 27 | $0.00 | |
| 91300 | 0% | 325 | $0.00 | |
| 91312 | 0% | 190 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 13 | $0.00 |
| 90685 | 0% | 53 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWARD, ELIZABETH (CFO/TREASURER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.